RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma.
Two aspects of cytokine therapy of intracerebral tumors are considered in this study: modulation of tumor growth in vivo and central nervous system toxicity. Coimplantation of RG-2 glioma cells and retroviral vector producer cell lines was performed to provide a local source of interleukin-2 (IL-2) or IFN-gamma within the tumor and coinitiate an antitumor immune response. We demonstrated that local intratumoral production of IL-2 and IFN-gamma generates a cell-mediated antitumor response in vivo. This response was manifest as a diffuse infiltration of monocytes/macrophages, CD4+ and CD8+ T cells, and activation of microglial OX42+ cells in intracerebral RG2 tumors. The cell-mediated antitumor immune response resulted in the early suppression of intracranial and subcutaneous tumor growth, but the effect was not sustained and there were no tumor regressions. The absence of increased survival of animals with intracranial tumors is explained in part by the severe central nervous system toxicity caused by local production of IL-2 and IFN-gamma. Central nervous system toxicity induced blood-brain barrier disruption, vasogenic brain edema, and dislocation of the brain midline structures, as observed by dynamic magnetic resonance imaging and direct measurements of tissue water content. The clinical application of IL-2 and IFN-gamma gene transfer therapy for intracerebral tumors must consider the potential for severe vasogenic brain edema associated with intracerebral production of these cytokines.
Tjuvajev
J
J
Cotzias Neuro-Oncology Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Gansbacher
B
B
Desai
R
R
Beattie
B
B
Kaplitt
M
M
Matei
C
C
Koutcher
J
J
Gilboa
E
E
Blasberg
R
R
D016475:3T3 Cells; D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D001812:Blood-Brain Barrier; D001929:Brain Edema / Q000209:etiology* / Q000378:metabolism*; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D002455:Cell Division / Q000502:physiology; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000378:metabolism; D018014:Gene Transfer Techniques / Q000009:adverse effects*; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors; D005910:Glioma / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000235:genetics / Q000494:pharmacology*; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000235:genetics / Q000494:pharmacology*; D008279:Magnetic Resonance Imaging; D051379:Mice; D051381:Rats; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic
D000912:Antibodies, Neoplasm; D007376:Interleukin-2; D007371:Interferon-gamma